CN109970749A - Hcv ns5a的抗病毒化合物抑制剂 - Google Patents

Hcv ns5a的抗病毒化合物抑制剂 Download PDF

Info

Publication number
CN109970749A
CN109970749A CN201811468769.0A CN201811468769A CN109970749A CN 109970749 A CN109970749 A CN 109970749A CN 201811468769 A CN201811468769 A CN 201811468769A CN 109970749 A CN109970749 A CN 109970749A
Authority
CN
China
Prior art keywords
base
imidazoles
naphtho
butyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811468769.0A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·O.·林克
杰瑞米·J.·柯特尔
特里萨·亚历杭德拉·特雷霍·马丁
伊丽莎白·M.·培根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Pharmasset Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Inc filed Critical Pharmasset Inc
Publication of CN109970749A publication Critical patent/CN109970749A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201811468769.0A 2012-05-16 2013-05-15 Hcv ns5a的抗病毒化合物抑制剂 Pending CN109970749A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261647966P 2012-05-16 2012-05-16
US61/647,966 2012-05-16
US13/831,116 US20130309196A1 (en) 2012-05-16 2013-03-14 Antiviral compounds
US13/831,116 2013-03-14
CN201380029171.0A CN104487442B (zh) 2012-05-16 2013-05-15 Hcv ns5a的抗病毒化合物抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380029171.0A Division CN104487442B (zh) 2012-05-16 2013-05-15 Hcv ns5a的抗病毒化合物抑制剂

Publications (1)

Publication Number Publication Date
CN109970749A true CN109970749A (zh) 2019-07-05

Family

ID=49581469

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201610856469.4A Expired - Fee Related CN106432254B (zh) 2012-05-16 2013-05-15 Hcv ns5a的抗病毒化合物抑制剂
CN201380029171.0A Active CN104487442B (zh) 2012-05-16 2013-05-15 Hcv ns5a的抗病毒化合物抑制剂
CN201811468769.0A Pending CN109970749A (zh) 2012-05-16 2013-05-15 Hcv ns5a的抗病毒化合物抑制剂

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201610856469.4A Expired - Fee Related CN106432254B (zh) 2012-05-16 2013-05-15 Hcv ns5a的抗病毒化合物抑制剂
CN201380029171.0A Active CN104487442B (zh) 2012-05-16 2013-05-15 Hcv ns5a的抗病毒化合物抑制剂

Country Status (19)

Country Link
US (5) US20130309196A1 (enExample)
EP (2) EP2850085B1 (enExample)
JP (2) JP6209209B2 (enExample)
KR (2) KR102078233B1 (enExample)
CN (3) CN106432254B (enExample)
AU (3) AU2013262874B2 (enExample)
BR (1) BR112014028221B1 (enExample)
CA (1) CA2873485C (enExample)
EA (2) EA034749B1 (enExample)
ES (2) ES2738012T3 (enExample)
HK (1) HK1245262B (enExample)
IL (1) IL235645A0 (enExample)
IN (1) IN2014MN02459A (enExample)
MX (1) MX362060B (enExample)
PL (2) PL3239153T3 (enExample)
PT (2) PT2850085T (enExample)
SG (2) SG10201703451RA (enExample)
SI (2) SI3239153T1 (enExample)
WO (1) WO2013173488A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2604620T2 (sl) 2003-05-30 2024-10-30 Gilead Pharmasset Llc Modificirani fluorirani nukleozidni analogi
CA3095528C (en) 2010-11-17 2023-07-18 Gilead Pharmasset Llc Antiviral compounds
UA119437C2 (uk) 2011-11-16 2019-06-25 Гайлід Фармассет Елелсі Противірусні сполуки
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
WO2015030854A1 (en) * 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) * 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
EP3473630B1 (en) 2014-07-02 2021-01-13 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
LT3236972T (lt) 2014-12-26 2021-11-10 Emory University Antivirusiniai n4-hidroksicitidino dariniai
MX384836B (es) 2016-03-07 2025-03-14 Enanta Pharm Inc Agentes antivirales contra la hepatitis b
WO2017191546A1 (en) * 2016-05-05 2017-11-09 Laurus Labs Private Ltd. Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors
WO2017205078A1 (en) 2016-05-27 2017-11-30 Gilead Sciences, Inc. Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
CN108368123B (zh) * 2016-07-08 2021-02-19 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
CN106220639A (zh) * 2016-07-22 2016-12-14 上海众强药业有限公司 一种维帕他韦中间体新晶型
CN107759577B (zh) * 2016-11-30 2020-03-27 上海博志研新药物技术有限公司 Gs5816中间体、制备方法及应用
EA202090514A1 (ru) 2017-08-28 2020-06-24 Энанта Фармасьютикалс, Инк. Противовирусное средство против гепатита в
CN107501280A (zh) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 一种维帕他韦的合成方法
LT3706762T (lt) 2017-12-07 2024-12-27 Emory University N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai
SG11202105007TA (en) 2018-11-21 2021-06-29 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
US12497362B2 (en) 2020-08-18 2025-12-16 Merck Sharp & Dohme Llc Cyclopentapyrrole orexin receptor agonists
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
AU2022277904B2 (en) 2021-05-21 2025-06-12 Gilead Sciences, Inc. Tetracyclic compounds for the treatment of zika virus infection
KR20240012476A (ko) * 2021-05-21 2024-01-29 길리애드 사이언시즈, 인코포레이티드 지카 바이러스 저해제로서의 펜타사이클릭 유도체

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007945A1 (en) * 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CN1820022A (zh) * 2003-05-09 2006-08-16 贝林格尔.英格海姆国际有限公司 丙型肝炎病毒ns5b聚合酶抑制剂结合袋
CN101754966A (zh) * 2007-05-17 2010-06-23 百时美施贵宝公司 丙型肝炎病毒抑制剂
WO2010096777A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2012068234A2 (en) * 2010-11-17 2012-05-24 Gilead Sciences, Inc. Antiviral compounds

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
AR050174A1 (es) 2004-07-16 2006-10-04 Gilead Sciences Inc Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ587323A (en) 2008-02-12 2012-02-24 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2008350334B2 (en) 2008-02-13 2013-10-17 Bristol-Myers Squibb Company Imidazolyl biphenyl imidazoles as hepatitis C virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
JP2012510523A (ja) 2008-12-03 2012-05-10 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
RU2544010C2 (ru) 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
CA2755658A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
AU2010249080A1 (en) 2009-05-12 2012-01-12 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
HUE036906T2 (hu) * 2009-05-13 2018-08-28 Antivirális vegyületek
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2012002759A (es) 2009-09-04 2012-04-30 Glaxosmithkline Llc Compuestos quimicos.
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2011066241A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
AR080676A1 (es) 2010-03-09 2012-05-02 Schering Corp Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US20130296311A1 (en) * 2010-05-28 2013-11-07 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
BR112013004520A2 (pt) 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
WO2012050918A2 (en) * 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
UA119437C2 (uk) * 2011-11-16 2019-06-25 Гайлід Фармассет Елелсі Противірусні сполуки
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007945A1 (en) * 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CN1820022A (zh) * 2003-05-09 2006-08-16 贝林格尔.英格海姆国际有限公司 丙型肝炎病毒ns5b聚合酶抑制剂结合袋
CN101754966A (zh) * 2007-05-17 2010-06-23 百时美施贵宝公司 丙型肝炎病毒抑制剂
WO2010096777A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2012068234A2 (en) * 2010-11-17 2012-05-24 Gilead Sciences, Inc. Antiviral compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIAOFAN ZHENG ET AL.: "Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
SI3239153T1 (sl) 2019-08-30
JP2017160276A (ja) 2017-09-14
EP3239153A1 (en) 2017-11-01
CN104487442A (zh) 2015-04-01
PL2850085T3 (pl) 2017-10-31
US20130309196A1 (en) 2013-11-21
MX2014013660A (es) 2015-04-17
IN2014MN02459A (enExample) 2015-07-10
KR20150008908A (ko) 2015-01-23
KR20200017557A (ko) 2020-02-18
AU2017248566A1 (en) 2017-11-09
BR112014028221A2 (pt) 2020-10-27
AU2019204423A1 (en) 2019-07-11
US20170342085A1 (en) 2017-11-30
CN104487442B (zh) 2016-10-26
CN106432254A (zh) 2017-02-22
PT2850085T (pt) 2017-06-26
ES2628350T3 (es) 2017-08-02
CA2873485A1 (en) 2013-11-21
EP2850085A1 (en) 2015-03-25
SG11201407533SA (en) 2014-12-30
CN106432254B (zh) 2018-12-28
MX362060B (es) 2019-01-07
AU2013262874B2 (en) 2017-11-02
US10800789B2 (en) 2020-10-13
JP6209209B2 (ja) 2017-10-04
ES2738012T3 (es) 2020-01-17
CA2873485C (en) 2020-05-05
AU2013262874A2 (en) 2015-01-22
PT3239153T (pt) 2019-07-30
HK1205126A1 (en) 2015-12-11
SI2850085T1 (sl) 2017-08-31
KR102078233B1 (ko) 2020-02-17
EP3239153B1 (en) 2019-05-08
EA034749B1 (ru) 2020-03-17
BR112014028221B1 (pt) 2022-05-03
US20190337960A1 (en) 2019-11-07
US20160115175A1 (en) 2016-04-28
US20140316144A1 (en) 2014-10-23
PL3239153T3 (pl) 2019-09-30
SG10201703451RA (en) 2017-06-29
AU2013262874A1 (en) 2014-12-11
EA201492002A1 (ru) 2015-11-30
EP2850085B1 (en) 2017-03-15
IL235645A0 (en) 2015-02-01
WO2013173488A1 (en) 2013-11-21
JP2015517527A (ja) 2015-06-22
HK1245262B (en) 2020-01-10
EA028026B1 (ru) 2017-09-29
JP6408656B2 (ja) 2018-10-17
US9682989B2 (en) 2017-06-20
EA201790963A1 (ru) 2018-02-28

Similar Documents

Publication Publication Date Title
CN106432254B (zh) Hcv ns5a的抗病毒化合物抑制剂
CN105837584B (zh) 作为抗病毒化合物的缩合的咪唑基咪唑
TWI640526B (zh) 抗病毒化合物
CN104230900B (zh) 抗病毒化合物
HK1245262A1 (en) 9-(1h-imidazol-5-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazole derivatives and their use as inhibitors of hcv ns5a
AU2019202345B2 (en) Antiviral Compounds
HK40009887A (en) Antiviral compounds inhibitors of hcv ns5a
HK1234741A1 (en) Antiviral compounds inhibitors of hcv ns5a
HK1234741A (en) Antiviral compounds inhibitors of hcv ns5a
HK1234741B (zh) Hcv ns5a的抗病毒化合物抑制剂
HK1227854A1 (en) Condensed imidazolylimidazoles as antiviral compounds
HK40035873A (en) Antiviral compounds
HK1227854B (zh) 作为抗病毒化合物的缩合的咪唑基咪唑
OA17167A (en) Condensed imidazolylimidazoles as antiviral compounds.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40009887

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20211206

Address after: California, USA

Applicant after: GILEAD SCIENCES, Inc.

Address before: California

Applicant before: GILEAD PHARMASSET LLC

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190705

WD01 Invention patent application deemed withdrawn after publication